|
1
|
Global progress report on HIV, viral
hepatitis and sexually transmitted infections, 2021. Accountability
for the global health sector strategies 2016-2021: actions for
impact(EB/OL). https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
|
|
2
|
Liu J, Liang W, Jing W and Liu M:
Countdown to 2030:Eliminating hepatitis B disease. Bull World
Health Organ. 97:230–238. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
European Association for the Study of the
Liver. EASL clinical practice guide-lines: Management of chronic
hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pan CQ, Hu KQ and Tsai N: Long-term
therapy with nucleoside/nucleotide analogues for chronic hepatitis
B in Asian patients. Antivir Ther. 18:841–852. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee
YS, Yoo YJ, Jung YK, Kim JH, Seo YS, et al: Early normalization of
alanine aminotransferase during antiviral therapy reduces risk of
hepatocellular carcinoma in HBV patients. J Clin Med.
10(1840)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chon YE, Kim SU, Seo YS, Lee HW, Lee HA,
Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, et al: Long-term effects
of entecavir and tenofovir treatment on the fibrotic burden in
patients with chronic hepatitis B. J Gastroen Hepatol. 37:200–207.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chinese Society of Hepatology, Chinese
Medical Association, Chinese Society of Infectious Diseases,
Chinese Medical Association. The guidelines of prevention and
treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi.
13:881–891. 2005.PubMed/NCBI(In Chinese).
|
|
8
|
Chinese Society of Hepatology and Chinese
Society of Infectious Diseases, Chinese Medical Association. The
guidelines of prevention and treatment for chronic hepatitis B
(2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24.
2011.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
9
|
Zhuang H and Weng XH: Development and
management of drug resistance to nucleoside/nucleotide analogues in
patients with chronic hepatitis B. Chin J Hepatol. 21:15–22.
2013.
|
|
10
|
Chinese Society of Hepatology, Chinese
Medical Association, Chinese Society of Infectious Diseases,
Chinese Medical Association. Hou JL and lai W: The Guidelines of
prevention and treatment for chronic hepatitis B: A 2015 update.
Zhonghua Gan Zang Bing Za Zhi. 23:888–905. 2015.(In Chinese).
|
|
11
|
Chinese Society of Infectious Diseases,
Chinese Medical Association, Chinese Society of Hepatology, Chinese
Medical Association. Guidelines of prevention and treatment for
chronic hepatitis B(2019 version). Zhonghua Gan Zang Bing Za Zhi.
27:938–961. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
12
|
European Association for the Study of the
Liver. Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Live. EASL 2017 clinical
practice guidelines on the management of hepatitis B virus
infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Terrault NA, Lok AS, McMahon BJ, Chang KM,
Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB: Update on
prevention, diagnosis, and treatment and of chronic hepatitis B:
AASLD 2018 hepatitis B guidance. J Hepatol. 67:1560–1599.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chinese Society of Hepatology Chinese
Medical Association, Chinese Society of Infectious Diseases,
Chinese Medical Association. Guidelines of prevention and treatment
for chronic hepatitis B(2022 version). Zhonghua Er Ke Za Zhi.
30:1309–1331. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
15
|
World Medical Association. World Medical
Association Declaration of Helsinki Ethical Principles for Medical
Research Involving Human Subjects. JAMA. 310:2191–2194.
2013.doi:10.1001/jama.2013.281053.
|
|
16
|
Tran TT: Management of hepatitis B in
pregnancy: Weighing the options. Cleve Clin J Med. 76 (Suppl
3):S25–S29. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Singh AE, Plitt SS, Osiowy C, Surynicz K,
Kouadjo E, Preiksaitis J and Lee B: Factors associated with vaccine
failure and vertical transmission of hepatitis B among a cohort of
Canadian mothers and infants. J Viral Hepat. 18:468–473.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Germer JJ, Qutub MO, Mandrekar JN,
Mitchell PS and Yao JD: Quantification of hepatitis B Virus (HBV)
DNA with a TaqMan HBV analyte-specific reagent following sample
processing with the MagNA pure LC Instrument. J Clin Microbiol.
44:1490–1494. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pan CQ, Zou H, Chen Y, Zhang X, Zhang H,
Li J and Duan Z: Cesarean section reduces perinatal transmission of
hepatitis B virus infection from hepatitis B surface
antigen-positive women to their infants. Clin Gastroenterol
Hepatol. 11:1349–1355. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Capital Institute of Pediatrics. The
Coordinating Study Group of Nine Cities on the Physical Growth and
Development of Children. A national survey on physical growth and
development of children under seven years of age in nine cities of
China in 2015. Zhonghua Er Ke Za Zhi. 56:192–199. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
21
|
Yang R, Yin N, Zhao Y, Li D, Zhang X, Li
X, Zhang Y and Faiola F: Adverse events during pregnancy associated
with entecavir and adefovir: New insights from a real-world
analysis of cases reported to FDA adverse event reporting system.
Front pharmacol. 12(772768)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S
and Qing Y: Genetic evidence for genotoxic effect of entecavir, an
anti-hepatitis B virus nucleotide analog. PLoS One.
11(e0147440)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
The Antiretroviral Pregnancy Registry.
Interim Report: 1 January 1989 through 31 January 2013 (R/OL)
(2013-09-30). https://www.apregistry.com/forms/interim_report.pdf.
|
|
24
|
Cai H, Ma X, Li R, et al: Retrospective
survey assessing pregnancy outcomes of partners of Chinese male
patients with chronic hepatitis B who received long-term Entecavir
treatment. Liver Int. 36 (Suppl)(S654)2014.
|
|
25
|
Peng J and Hou J: Current situation and
management of pregnancy and anti-HBV treatment. Chin J Hepatol.
19:236–238. 2011.
|
|
26
|
Cao LH, Zhao PL, Liu ZM, Sun SC, Xu DB,
Zhang JD and Shao MH: Efficacy and safety of nucleoside analogs on
blocking father-to-infant vertical transmission of hepatitis B
virus. Exp Ther Med. 9:2251–2256. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cao L, Li Y, Wang S, et al: Clinical
research on the blocking effect of nucleoside analogue on HBV
father-to-infant transmission. Chin J Exp Clin Virol. 29:251–253.
2015.
|
|
28
|
Corbett AH, Kayira D, White NR, Davis NL,
Kourtis AP, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D,
et al: Antiretroviral pharmacokinetics in mothers and breastfeeding
infants from 6 to 24 weeks postpartum: Results of the BAN Study.
Antivir Ther. 19:587–595. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Benaboud S, Pruvost A, Coffie PA, Ekouévi
DK, Urien S, Arrivé E, Blanche S, Théodoro F, Avit D, Dabis F, et
al: Concentrations of tenofovir and emtricitabine in breast milk of
HIV-1-infected women in Abidjan, Cote d'lvoire, in the ANRS 12109
TEmAA Study, Step 2. Antimicrob Agents Chemother. 55:1315–1317.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chen S, Shi Y, Yu D, et al: Influence of
different state of HBV co-infections of couples on pregnancy rate,
pregnancy outcomes and maternal-infant outcomes of patients treated
by IVF/ICSI-ET. Chin J Nosocomiology. 31:3031–3035. 2021.
|
